FGFR3 and cancer: Additionally, a phase II/III clinical trial comparing Rogaratinib, a novel targeted therapy for FGFR3-driven cancers, with chemotherapy has shown comparable efficacy and a favorable safety profile in patients with FGFR3 genetic abnormalities [47].